Abstract
Background: In order to increase the rate of curative resection and improve the prognosis for borderline resectable pancreatic adenocarcinoma (BR-PDAC), neoadjuvant therapy (NAT) has been adopted. However, sufficient evidence has not been established and therapeutic strategies for BR-PDAC differ from institution to institution. Multicentre retrospective study was performed to reveal the therapeutic strategies and outcome in patients with BR-PDAC.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
